Tyler Jacks

List of Publications by Year
in descending order

240 papers	95,482 citations	735 120 h-index	1051 234 g-index
252 all docs	252 docs citations	252 times ranked	82223 citing authors

#	Article	IF	Citations
1	Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. Cancer Discovery, 2022, 12, 562-585.	9.4	48
2	A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells. Nature Communications, 2022, 13, 256.	12.8	8
3	Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. Nature, 2022, 601, 85-91.	27.8	117
4	Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell, 2022, 185, 1905-1923.e25.	28.9	108
5	Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature, 2022, 607, 149-155.	27.8	38
6	Inducible de novo expression of neoantigens in tumor cells and mice. Nature Biotechnology, 2021, 39, 64-73.	17.5	32
7	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	62
8	Protocol for single-cell ATAC sequencing using combinatorial indexing in mouse lung adenocarcinoma. STAR Protocols, 2021, 2, 100583.	1.2	9
9	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	20
10	Rlfâ€“Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 3214-3229.	9.4	24
11	Live cell tagging tracking and isolation for spatial transcriptomics using photoactivatable cell dyes. Nature Communications, 2021, 12, 4995.	12.8	25
12	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell, 2021, 39, 1342-1360.e14.	16.8	119
13	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nature Cancer, 2021, 2, 1071-1085.	13.2	57
14	Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. Nature Communications, 2021, 12, 5680.	12.8	18
15	Antigen dominance hierarchies shape TCF1+ progenitor CD8 TÂcell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26.	28.9	84
16	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ TÂcells in tumor-draining lymph nodes. Immunity, 2021, 54, 2338-2353.e6.	14.3	111
17	BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. Cancer Research, 2020, 80, 3841-3854.	0.9	32
18	Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. Cancer Cell, 2020, 38, 212-228.e13.	16.8	140

#	Article	IF	Citations
19	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell, 2020, 38, 229-246.e13.	16.8	210
20	Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nature Cancer, 2020, 1, 589-602.	13.2	44
21	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Science Translational Medicine, 2020, 12, .	12.4	58
22	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell, 2020, 181, 832-847.e18.	28.9	77
23	CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 513-521.	7.1	54
24	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. ELife, 2020, 9, .	6.0	61
25	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science, 2019, 365, 599-604.	12.6	265
26	Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium. Nature, 2019, 571, 398-402.	27.8	166
27	Identification of DHODH as a therapeutic target in small cell lung cancer. Science Translational Medicine, 2019, 11, .	12.4	89
28	Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17460-17469.	7.1	50
29	Commensal Microbiota Promote Lung Cancer Development via Î³Î´ T Cells. Cell, 2019, 176, 998-1013.e16.	28.9	592
30	IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development. Cell Reports, 2019, 29, 2998-3008.e8.	6.4	53
31	MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature, 2019, 574, 696-701.	27.8	563
32	Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Research, 2018, 78, 985-1002.	0.9	35
33	Colonoscopy-based colorectal cancer modeling in mice with CRISPRâ€“Cas9 genome editing and organoid transplantation. Nature Protocols, 2018, 13, 217-234.	12.0	74
34	Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Nano Letters, 2018, 18, 2195-2208.	9.1	20
35	Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer & Metabolism, 2018, 6, 6.	5.0	24
36	A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature, 2017, 545, 355-359.	27.8	265

#	Article	IF	Citations
37	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nature Biotechnology, 2017, 35, 569-576.	17.5	248
38	Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1â€“3 family. Genes and Development, 2017, 31, 674-687.	5.9	16
39	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature Medicine, 2017, 23, 1362-1368.	30.7	462
40	Survival of pancreatic cancer cells lacking KRAS function. Nature Communications, 2017, 8, 1090.	12.8	131
41	Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5625-E5634.	7.1	116
42	Basic Mouse Methods for Clinician Researchers. , 2017, , 291-312.		2
43	Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. Cell, 2016, 165, 896-909.	28.9	195
44	Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes and Development, 2016, 30, 1020-1033.	5.9	122
45	Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras -driven cancers. Science, 2016, 353, 1161-1165.	12.6	447
46	Mutational landscape of EGFR- , MYC- , and Kras- driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6409-E6417.	7.1	158
47	Circadian Rhythm Disruption Promotes Lung Tumorigenesis. Cell Metabolism, 2016, 24, 324-331.	16.2	366
48	Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. Nature Communications, 2016, 7, 12685.	12.8	58
49	A Modular Assembly Platform for Rapid Generation of DNA Constructs. Scientific Reports, 2016, 6, 16836.	3.3	54
50	<scp>PKM</scp> 2, cancer metabolism, and the road ahead. EMBO Reports, 2016, 17, 1721-1730.	4.5	384
51	Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. Cancer Discovery, 2016, 6, 188-201.	9.4	122
52	Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. Cell Metabolism, 2016, 23, 517-528.	16.2	616
53	Applications of the CRISPRâ€“Cas9 system in cancer biology. Nature Reviews Cancer, 2015, 15, 387-393.	28.4	340
54	Recombinase-based conditional and reversible gene regulation via XTR alleles. Nature Communications, 2015, 6, 8783.	12.8	31

#	Article	IF	Citations
55	A versatile reporter system for CRISPR-mediated chromosomal rearrangements. Genome Biology, 2015, 16, 111.	9.6	52
56	The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung. Journal of Thoracic Oncology, 2015, 10, 553-564.	1.1	100
57	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	30.7	349
58	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity, 2015, 43, 579-590.	14.3	360
59	Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes and Development, 2015, 29, 1850-1862.	5.9	87
60	Genetic Mouse Models of Cancer. , 2015, , 145-154.e2.		5
61	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology, 2014, 32, 551-553.	17.5	823
62	Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. Cell, 2014, 156, 1298-1311.	28.9	241
63	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature, 2014, 516, 428-431.	27.8	353
64	Small RNA combination therapy for lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3553-61.	7.1	210
65	CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature, 2014, 514, 380-384.	27.8	673
66	Autophagy Is Required for Glucose Homeostasis and Lung Tumor Maintenance. Cancer Discovery, 2014, 4, 914-927.	9.4	450
67	LincRNA-p21 Activates p21 In cis to Promote Polycomb Target Gene Expression and to Enforce the G1/S Checkpoint. Molecular Cell, 2014, 54, 777-790.	9.7	412
68	KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell, 2014, 158, 171-184.	28.9	608
69	A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response InÂVivo. Cell Reports, 2013, 5, 868-877.	6.4	85
70	PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells. Cell, 2013, 155, 397-409.	28.9	429
71	Nkx2-1 Represses a Latent Gastric Differentiation Program in Lung Adenocarcinoma. Molecular Cell, 2013, 50, 185-199.	9.7	215
72	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Current Opinion in Immunology, 2013, 25, 192-199.	5.5	76

#	Article	IF	Citations
73	Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes and Development, 2013, 27, 197-210.	5.9	61
74	Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes and Development, 2013, 27, 1557-1567.	5.9	62
75	Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic Transformation. Cancer Discovery, 2013, 3, 993-1001.	9.4	60
76	Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes and Development, 2013, 27, 1447-1461.	5.9	529
77	Pten-Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction. Cancer Discovery, 2013, 3, 908-921.	9.4	36
78	Characterizing deformability and surface friction of cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7580-7585.	7.1	297
79	SnapShot: Lung Cancer Models. Cell, 2012, 149, 246-246.e1.	28.9	36
80	Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 2012, 482, 405-409.	27.8	478
81	Proliferation and Tumorigenesis of a Murine Sarcoma Cell Line in the Absence of DICER1. Cancer Cell, 2012, 21, 848-855.	16.8	58
82	Nuclear factor I/B is an oncogene in small cell lung cancer. Genes and Development, 2011, 25, 1470-1475.	5.9	142
83	Caspase-2-Mediated Cleavage of Mdm2 Creates a p53-Induced Positive Feedback Loop. Molecular Cell, 2011, 43, 57-71.	9.7	139
84	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8773-8778.	7.1	213
85	Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood, 2011, 117, 2022-2032.	1.4	132
86	Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5qâ˜' syndrome. Blood, 2011, 118, 4666-4673.	1.4	97
87	Suppression of lung adenocarcinoma progression by Nkx2-1. Nature, 2011, 473, 101-104.	27.8	383
88	Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression. Cancer Cell, 2011, 19, 72-85.	16.8	209
89	Requirement of c-Jun NH₂-Terminal Kinase for Ras-Initiated Tumor Formation. Molecular and Cellular Biology, 2011, 31, 1565-1576.	2.3	93
90	Response and Resistance to NF-Î²B Inhibitors in Mouse Models of Lung Adenocarcinoma. Cancer Discovery, 2011, 1, 236-247.	9.4	116

#	Article	IF	Citations
91	Uncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis. Cancer Research, 2011, 71, 4040-4047.	0.9	76
92	Progressive Genomic Instability in the FVB/KrasLA2 Mouse Model of Lung Cancer. Molecular Cancer Research, 2011, 9, 1339-1345.	3.4	21
93	Imaging Primary Lung Cancers in Mice to Study Radiation Biology. International Journal of Radiation Oncology Biology Physics, 2010, 76, 973-977.	0.8	57
94	Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature, 2010, 468, 572-575.	27.8	255
95	Chimeric mouse tumor models reveal differences in pathway activation between ERBB familyâ€“ and KRAS-dependent lung adenocarcinomas. Nature Biotechnology, 2010, 28, 71-78.	17.5	71
96	Tissue-specific p19 ^{Arf} regulation dictates the response to oncogenic K-ras. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10184-10189.	7.1	54
97	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes and Development, 2010, 24, 837-852.	5.9	174
98	HIF-2Î± deletion promotes Kras-driven lung tumor development. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14182-14187.	7.1	117
99	Suppression of Rev3, the catalytic subunit of PolÎ¶, sensitizes drug-resistant lung tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20786-20791.	7.1	160
100	NF-ÎºB Fans the Flames of Lung Carcinogenesis. Cancer Prevention Research, 2010, 3, 403-405.	1.5	27
101	A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response. Cell, 2010, 142, 409-419.	28.9	1,919
102	p63 and p73 Transcriptionally Regulate Genes Involved in DNA Repair. PLoS Genetics, 2009, 5, e1000680.	3.5	120
103	Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras. Cancer Cell, 2009, 16, 379-389.	16.8	305
104	Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature, 2009, 458, 223-227.	27.8	3,801
105	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009, 462, 108-112.	27.8	2,707
106	Requirement for NF-ÎºB signalling in a mouse model of lung adenocarcinoma. Nature, 2009, 462, 104-107.	27.8	483
107	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protocols, 2009, 4, 1064-1072.	12.0	711
108	Dicer1 functions as a haploinsufficient tumor suppressor. Genes and Development, 2009, 23, 2700-2704.	5.9	391

#	Article	IF	Citations
109	MicroRNAs and Cancer: Short RNAs Go a Long Way. Cell, 2009, 136, 586-591.	28.9	824
110	Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells. Cell, 2009, 137, 821-834.	28.9	510
111	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics, 2008, 40, 600-608.	21.4	514
112	Genetic Mouse Models of Cancer. , 2008, , 129-138.		0
113	A mouse plasma PeptideAtlas as a resource for disease proteomics. Genome Biology, 2008, 9, R93.	9.6	22
114	Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17â^¼92 Family of miRNA Clusters. Cell, 2008, 132, 875-886.	28.9	1,504
115	Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression. Cell, 2008, 134, 62-73.	28.9	381
116	Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3903-3908.	7.1	808
117	Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer. Cancer Research, 2008, 68, 9459-9468.	0.9	45
118	Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes and Development, 2007, 21, 694-707.	5.9	120
119	Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- 1 haploinsufficiency. Carcinogenesis, 2007, 28, 2589-2596.	2.8	11
120	Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage. Cancer Research, 2007, 67, 4648-4656.	0.9	40
121	Requirement for Rac1 in a K-rasâ€“Induced Lung Cancer in the Mouse. Cancer Research, 2007, 67, 8089-8094.	0.9	148
122	Roles of microRNAs in cancer and development. , 2007, , 322-337.		0
123	Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics, 2007, 39, 673-677.	21.4	1,351
124	A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine, 2007, 13, 992-997.	30.7	274
125	Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO Journal, 2007, 26, 784-794.	7.8	69
126	Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445, 661-665.	27.8	1,662

#	Article	IF	Citations
127	A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nature Genetics, 2006, 38, 926-930.	21.4	67
128	Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes and Cancer, 2006, 45, 338-348.	2.8	42
129	Mist1-KrasG12D Knock-In Mice Develop Mixed Differentiation Metastatic Exocrine Pancreatic Carcinoma and Hepatocellular Carcinoma. Cancer Research, 2006, 66, 242-247.	0.9	132
130	Cyclooxygenase-1 Is Overexpressed in Multiple Genetically Engineered Mouse Models of Epithelial Ovarian Cancer. Cancer Research, 2006, 66, 2527-2531.	0.9	70
131	The Related Retinoblastoma (pRb) and p130 Proteins Cooperate to Regulate Homeostasis in the Intestinal Epithelium. Journal of Biological Chemistry, 2006, 281, 638-647.	3.4	66
132	ROS Fusion Tyrosine Kinase Activates a SH2 Domainâ€“Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice. Cancer Research, 2006, 66, 7473-7481.	0.9	145
133	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nature Genetics, 2005, 37, 48-55.	21.4	392
134	Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nature Medicine, 2005, 11, 63-70.	30.7	785
135	MicroRNA expression profiles classify human cancers. Nature, 2005, 435, 834-838.	27.8	8,931
136	Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell, 2005, 7, 363-373.	16.8	455
137	Mammalian RNAi: a practical guide. BioTechniques, 2005, 39, 215-224.	1.8	121
138	The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Research, 2005, 65, 10280-10288.	0.9	488
139	Lack of p53 Ser389 Phosphorylation Predisposes Mice to Develop 2-Acetylaminofluoreneâ€“Induced Bladder Tumors but not Ionizing Radiationâ€“Induced Lymphomas. Cancer Research, 2005, 65, 3610-3616.	0.9	35
140	Future of Early Detection of Lung Cancer: The Role of Mouse Models. Clinical Cancer Research, 2005, 11, 4999s-5003s.	7.0	20
141	Mice Expressing a Mammary Glandâ€“Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development. Cancer Research, 2005, 65, 8166-8173.	0.9	59
142	Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14404-14409.	7.1	133
143	Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer. Cell, 2005, 121, 823-835.	28.9	2,023
144	p53 Family Members: p63 and p73. , 2005, , 187-198.		1

#	Article	IF	Citations
145	Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389. Molecular and Cellular Biology, 2004, 24, 8884-8894.	2.3	116
146	Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13008-13013.	7.1	89
147	Cre-lox-regulated conditional RNA interference from transgenes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10380-10385.	7.1	575
148	Cell type-specific effects of Rb deletion in the murine retina. Genes and Development, 2004, 18, 1681-1694.	5.9	208
149	RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Research, 2004, 32, 25-34.	14.5	87
150	Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO Journal, 2004, 23, 3689-3699.	7.8	116
151	The Rb tumor suppressor is required for stress erythropoiesis. EMBO Journal, 2004, 23, 4319-4329.	7.8	91
152	Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene, 2004, 23, 973-980.	5.9	97
153	Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene, 2004, 23, 4107-4120.	5.9	41
154	Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene, 2004, 23, 7644-7650.	5.9	18
155	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell, 2004, 5, 375-387.	16.8	710
156	Classification of Proliferative Pulmonary Lesions of the Mouse. Cancer Research, 2004, 64, 2307-2316.	0.9	313
157	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell, 2004, 119, 847-860.	28.9	1,140
158	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. Journal of Clinical Investigation, 2004, 113, 528-538.	8.2	231
159	A big step in the study of small cell lung cancer. Cancer Cell, 2003, 4, 163-166.	16.8	50
160	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003, 4, 437-450.	16.8	2,150
161	Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types. Current Biology, 2003, 13, 1985-1990.	3.9	97
162	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature, 2003, 424, 223-228.	27.8	501

#	Article	IF	Citations
163	Merlin, the Product of the Nf2 Tumor Suppressor Gene, Is an Inhibitor of the p21-Activated Kinase, Pak1. Molecular Cell, 2003, 12, 841-849.	9.7	222
164	Recapitulation of the Effects of the Human Papillomavirus Type 16 E7 Oncogene on Mouse Epithelium by Somatic Rb Deletion and Detection of pRb-Independent Effects of E7 In Vivo. Molecular and Cellular Biology, 2003, 23, 9094-9103.	2.3	103
165	Targeted Deletion Reveals an Essential Function for the Telomere Length Regulator Trf1. Molecular and Cellular Biology, 2003, 23, 6533-6541.	2.3	150
166	Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes and Development, 2003, 17, 449-454.	5.9	120
167	Neurofibromatosis Type 1. , 2003, 222, 223-237.		5
168	Marked Regression of Metastatic Pilocytic Astrocytoma During Treatment With Imatinib Mesylate (STI-571, Gleevec): A Case Report and Laboratory Investigation. Journal of Pediatric Hematology/Oncology, 2003, 25, 644-648.	0.6	21
169	Rb and N- ras Function Together To Control Differentiation in the Mouse. Molecular and Cellular Biology, 2003, 23, 5256-5268.	2.3	49
170	Merlin Phosphorylation by p21-activated Kinase 2 and Effects of Phosphorylation on Merlin Localization. Journal of Biological Chemistry, 2002, 277, 10394-10399.	3.4	213
171	Tumor Suppression by a Severely Truncated Species of Retinoblastoma Protein. Molecular and Cellular Biology, 2002, 22, 3103-3110.	2.3	25
172	ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16865-16870.	7.1	42
173	Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2948-2953.	7.1	176
174	Cancer Modeling in the Modern Era. Cell, 2002, 108, 135-144.	28.9	348
175	An Induced Ets Repressor Complex Regulates Growth Arrest during Terminal Macrophage Differentiation. Cell, 2002, 109, 169-180.	28.9	90
176	Taking the Study of Cancer Cell Survival to a New Dimension. Cell, 2002, 111, 923-925.	28.9	279
177	Technologically advanced cancer modeling in mice. Current Opinion in Genetics and Development, 2002, 12, 105-110.	3.3	77
178	Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin. Molecular Immunology, 2002, 38, 701-708.	2.2	25
179	Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. Cancer Cell, 2002, 1, 408-410.	16.8	30
180	ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos. Current Biology, 2002, 12, 159-163.	3.9	70

#	Article	IF	Citations
181	Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene, 2002, 21, 5990-5997.	5.9	42
182	Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature, 2002, 415, 526-530.	27.8	541
183	p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature, 2002, 416, 560-564.	27.8	775
184	The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling. Developmental Cell, 2001, 1, 63-72.	7.0	311
185	NF1 Tumor Suppressor Gene Function. Cell, 2001, 104, 593-604.	28.9	553
186	Genetically engineered mouse models of astrocytoma: GEMs in the rough?. Seminars in Cancer Biology, 2001, 11, 177-190.	9.6	28
187	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 2001, 20, 5054-5058.	5.9	643
188	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 2001, 410, 1111-1116.	27.8	1,060
189	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes and Development, 2001, 15, 3243-3248.	5.9	1,663
190	Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nature Genetics, 2000, 26, 109-113.	21.4	379
191	Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature, 2000, 407, 645-648.	27.8	656
192	Targeted disruption of the three Rb-related genes leads to loss of G₁ control and immortalization. Genes and Development, 2000, 14, 3037-3050.	5.9	546
193	Nf1 and Gmcsf Interact in Myeloid Leukemogenesis. Molecular Cell, 2000, 5, 189-195.	9.7	132
194	PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes and Development, 2000, 14, 704-718.	5.9	310
195	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells. Blood, 1999, 94, 2469-2476.	1.4	81
196	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood, 1999, 93, 3617-3623.	1.4	55
197	Modeling human lung cancer in mice: similarities and shortcomings. Oncogene, 1999, 18, 5318-5324.	5.9	121
198	The retinoblastoma gene family in differentiation and development. Oncogene, 1999, 18, 7873-7882.	5.9	362

#	Article	IF	Citations
199	Insights into cancer from transgenic mouse models. Journal of Pathology, 1999, 187, 43-60.	4.5	113
200	Mouse Models of Tumor Development in Neurofibromatosis Type 1 . Science, 1999, 286, 2172-2176.	12.6	441
201	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood, 1999, 93, 3617-3623.	1.4	6
202	Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/â˜) mice. Nature Genetics, 1998, 18, 360-364.	21.4	274
203	Tumor suppressor mutations in mice: the next generation. Current Opinion in Genetics and Development, 1998, 8, 304-310.	3.3	15
204	Mutation of E2f-1 Suppresses Apoptosis and Inappropriate S Phase Entry and Extends Survival of Rb-Deficient Mouse Embryos. Molecular Cell, 1998, 2, 293-304.	9.7	361
205	p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells. Journal of Cell Biology, 1998, 141, 503-514.	5.2	145
206	Regulation of the Neurofibromatosis Type 2 Tumor Suppressor Protein, Merlin, by Adhesion and Growth Arrest Stimuli. Journal of Biological Chemistry, 1998, 273, 7757-7764.	3.4	113
207	Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines. Journal of Experimental Medicine, 1998, 187, 1893-1902.	8.5	140
208	RhoA-Dependent Phosphorylation and Relocalization of ERM Proteins into Apical Membrane/Actin Protrusions in Fibroblasts. Molecular Biology of the Cell, 1998, 9, 403-419.	2.1	171
209	p130 Is Dispensable in Peripheral T Lymphocytes: Evidence for Functional Compensation by p107 and pRB. Molecular and Cellular Biology, 1998, 18, 206-220.	2.3	81
210	Involvement of p53 and p21 in Cellular Defects and Tumorigenesis in Atm â˜'/â˜' Mice. Molecular and Cellular Biology, 1998, 18, 4385-4390.	2.3	94
211	Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption. Molecular and Cellular Biology, 1998, 18, 1055-1064.	2.3	466
212	A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nature Genetics, 1997, 15, 281-284.	21.4	336
213	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nature Genetics, 1997, 16, 336-337.	21.4	16
214	Double indemnity: p53, BRCA and cancer. Nature Medicine, 1997, 3, 721-722.	30.7	105
215	TUMOR SUPPRESSOR GENE MUTATIONS IN MICE. Annual Review of Genetics, 1996, 30, 603-636.	7.6	104
216	Tumor Induction and Tissue Atrophy in Mice Lacking E2F-1. Cell, 1996, 85, 537-548.	28.9	671

#	Article	IF	Citations
217	Mechanisms of carcinogenesis and the mutant mouse. Current Opinion in Genetics and Development, 1996, 6, 65-70.	3.3	26
218	Lessons from thep53 mutant mouse. Journal of Cancer Research and Clinical Oncology, 1996, 122, 319-327.	2.5	33
219	Nf1gene targeting: toward models and mechanisms. Seminars in Cancer Biology, 1996, 7, 291-298.	9.6	10
220	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genetics, 1996, 12, 144-148.	21.4	555
221	Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996, 379, 88-91.	27.8	2,223
222	Cell-cycle control and its watchman. Nature, 1996, 381, 643-644.	27.8	278
223	A subset of p53-deficient embryos exhibit exencephaly. Nature Genetics, 1995, 10, 175-180.	21.4	544
224	Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 1995, 377, 552-557.	27.8	1,218
225	Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase-activating protein. Nature, 1995, 377, 695-701.	27.8	357
226	Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocrine Pathology, 1995, 6, 323-335.	9.0	40
227	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature Genetics, 1994, 7, 353-361.	21.4	731
228	Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genetics, 1994, 7, 480-484.	21.4	379
229	p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature, 1994, 371, 72-74.	27.8	625
230	Sunburn and p53 in the onset of skin cancer. Nature, 1994, 372, 773-776.	27.8	1,724
231	Tumor spectrum analysis in p53-mutant mice. Current Biology, 1994, 4, 1-7.	3.9	1,903
232	p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 1994, 78, 703-711.	28.9	873
233	p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 1993, 362, 847-849.	27.8	2,829
234	Generation of normal lymphocyte populations by Rb-deficient embryonic stem cells. Current Biology, 1993, 3, 405-413.	3.9	37

#	Article	IF	Citations
235	p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 1993, 74, 957-967.	28.9	2,848
236	Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 1992, 70, 923-935.	28.9	1,345
237	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 1992, 71, 587-597.	28.9	3,006
238	Effects of an Rb mutation in the mouse. Nature, 1992, 359, 295-300.	27.8	1,730
239	Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature, 1988, 331, 280-283.	27.8	928
240	Signals for ribosomal frameshifting in the rous sarcoma virus gag-pol region. Cell, 1988, 55, 447-458.	28.9	647